Gerimal
Gerimal Brand names, Gerimal Analogs
- Alkergot
- Circanol
- Co-Dergocrine Mesylate
- Deapril-ST
- Dihydroergotoxin Mesilat
- Dihydroergotoxin Mesylate
- Dihydroergotoxin Methanesulfonate
- Dihydroergotoxine Mesilate
- Dihydroergotoxine Mesylate
- Dihydroergotoxine Methanesulfonate
- Dihydroergotoxine Methanesulphonate
- Ergoloid Mesylates [Usan]
- Gerimal
- Hydergin
- Hydergine
- Hydergine LC
- Hydrogenated Ergot Alkaloids
- Ischelium
- Redergin
- Trigot
Gerimal Brand Names Mixture
- No information avaliable
Gerimal Chemical_Formula
C33H45N5O5
Gerimal RX_link
No information avaliable
Gerimal fda sheet
Gerimal msds (material safety sheet)
Gerimal Synthesis Reference
No information avaliable
Gerimal Molecular Weight
591.741 g/mol
Gerimal Melting Point
No information avaliable
Gerimal H2O Solubility
No information avaliable
Gerimal State
Solid
Gerimal LogP
2.615
Gerimal Dosage Forms
Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet
Gerimal Indication
For use as an adjunct therapy for patients with dementia
Gerimal Pharmacology
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Gerimal Absorption
Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Gerimal side effects and Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Gerimal Patient Information
No information avaliable
Gerimal Organisms Affected
Humans and other mammals
